Financial reports
10-K/A
2023 FY
Annual report (amended)
16 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
3 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
22 Apr 24
8-K
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
9 Apr 24
8-K
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
29 Mar 24
8-K
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
27 Mar 24
8-K
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
30 Jan 24
8-K
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
2 Jan 24
8-K
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
18 Dec 23
8-K
Entry into a Material Definitive Agreement
18 Dec 23
8-K
Other Events
29 Nov 23
8-K
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
27 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Apr 24
8-A12B/A
Registration of securities on exchange (amended)
18 Dec 23
424B5
Prospectus supplement for primary offering
16 Aug 23
S-8
Registration of securities for employees
20 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jun 23
8-A12B/A
Registration of securities on exchange (amended)
12 Dec 22
8-A12B/A
Registration of securities on exchange (amended)
21 Dec 21
424B3
Prospectus supplement
21 Sep 21
S-3
Shelf registration
7 Sep 21
424B5
Prospectus supplement for primary offering
15 Jul 21
Proxies
DEF 14A
Definitive proxy
21 Apr 23
DEF 14A
Definitive proxy
19 Apr 22
DEF 14A
Definitive proxy
26 Apr 21
DEF 14A
Definitive proxy
21 Aug 20
DEF 14A
Definitive proxy
9 Aug 19
PRE 14A
Preliminary proxy
29 Jul 19
Other
UPLOAD
Letter from SEC
10 Apr 23
CORRESP
Correspondence with SEC
31 Mar 23
UPLOAD
Letter from SEC
28 Mar 23
EFFECT
Notice of effectiveness
20 Sep 21
CORRESP
Correspondence with SEC
15 Sep 21
UPLOAD
Letter from SEC
13 Sep 21
EFFECT
Notice of effectiveness
6 May 21
EFFECT
Notice of effectiveness
6 May 21
CORRESP
Correspondence with SEC
3 May 21
CORRESP
Correspondence with SEC
3 May 21
Ownership
4
Scott Juda
13 Nov 23
4
Timothy j Schroeder
14 Jul 23
144
Notice of proposed sale of securities
12 Jul 23
4
David J Moss
20 Mar 23
4
Raymond Joseph Tesi
21 Feb 23
4
Scott Juda
21 Feb 23
4
Timothy j Schroeder
21 Feb 23
4
David J Moss
21 Feb 23
4
James Kelly Ganjei
21 Feb 23
4
Edgardo Baracchini Jr
21 Feb 23